Lenvatinib prolongs the progression‑free survival time of patients with intermediate‑stage hepatocellular carcinoma refractory to transarterial chemoembolization: A multicenter cohort study using data mining analysisShigeo Shimose, Takuji Torimura, Tomotake Shirono et al.|Oncology Letters|2020Cited by 64
Prognostic impact of transcatheter arterial chemoembolization (TACE) combined with radiofrequency ablation in patients with unresectable hepatocellular carcinoma: Comparison with TACE alone using decision‐tree analysis after propensity score matchingShigeo Shimose, Takuji Torimura, Masatoshi Tanaka et al.|Hepatology Research|2019Cited by 48
Controlling Nutritional Status (CONUT) Score is Associated with Overall Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Cohort StudyShigeo Shimose, Takuji Torimura, Takumi Kawaguchi et al.|Nutrients|2020Cited by 47
First‐line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: A multicenter retrospective studyShigeo Shimose, Takuji Torimura, Atsushi Hiraoka et al.|Cancer Medicine|2021Cited by 16